The DOI matches its Crossref record; 17 of the 19 references it cites were found in a registry or an index.
Characteristics and food consumption for current, previous, and potential consumers of GLP-1 s
Open accessAbstract
Widespread adoption of Glucagon-like peptide-1 (GLP-1) agonists could cause significant changes in food consumption and preferences that disrupt the food industry. In this study, we survey four consumer groups to better understand how GLP-1 s may affect food consumption and preferences. The four groups were: 1) consumers currently using a GLP-1, 2) consumers who have previously used a GLP-1, 3) consumers who haven't used a GLP-1 but plan to in the future, and 4) consumers who haven't used a GLP-1 and don't plan to in the future. Results show that consumers currently taking a GLP-1 consume significantly fewer calories than the other groups surveyed, and calorie reduction while taking a GLP-1 for weight loss could be around 720 to 990 cal. Additionally, those taking GLP-1 s most likely reduce consumption of processed foods, sugar-sweetened beverages, refined grains, and beef. The results of this study will inform potential consumers and food companies of valuable insights into the broader effects of GLP-1 s on caloric intake and food preferences. • The consumer market for Glucagon-like peptide-1 (GLP-1) agonists is significant. • We surveyed four consumer groups, including those who had or are taking a GLP-1. • Gender, household size, and education were associated with GLP-1 use and interest. • Intake recall suggests that GLP-1 users reduce consumption more than 700 cal. • GLP-1 users reduced consumption of processed foods, soda, refined grains, and beef.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There is some evidence that people taking these new medications may develop healthier eating habits, with stores in the USA reporting declining food sales as GLP-1RA medication use rises.141”
From The societal implications of using glucagon-like peptide-1 receptor agonists for the treatment of obesity (2025) · cites this paper as [141]
In the citing paper
“There is some evidence that people taking these new medications may develop healthier eating habits, with stores in the USA reporting declining food sales as GLP-1RA medication use rises.141”
From The societal implications of using glucagon-like peptide-1 receptor agonists for the treatment of obesity (2025) · cites this paper as [141]
In the citing paper
“For example, GLP-1 based therapy has been associated with a reduction in the consumption of meat (beef, pork and fish) and therefore reduced protein intake, which can lead ultimately to accelerated reduction of LBM and reduced muscle mass, strength and function [67].”
From Application of nutrition interventions with GLP-1 based therapies: A narrative review of the challenges and solutions (2025) · cites this paper as [67]
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Data quality of platforms and panels for online behavioral research
Peer, E., Rothschild, D., Gordon, A., Evernden, Z., & Damer, E. (2021) · Behavior Research Methods · doi:10.3758/s13428-021-01694-3 · Cited by 1,718
Douglas, B. D., Ewell, P. J., & Brauer, M. (2023) · PLOS ONE · doi:10.1371/journal.pone.0279720 · Cited by 1,532
Aronne, L. J., Sattar, N., Horn, D. B., Bays, H. E., Wharton, S., Lin, W.-Y., Ahmad, N. N., Zhang, S., Liao, R., Bunck, M. C., et al. (2024) · JAMA · doi:10.1001/jama.2023.24945 · Cited by 860
on behalf of the NN8022-1807 Investigators, Astrup, A., Carraro, R., Finer, N., Harper, A., Kunesova, M., Lean, M. E. J., Niskanen, L., Rasmussen, M. F., Rissanen, A., et al. (2012) · International Journal of Obesity · doi:10.1038/ijo.2011.158 · Cited by 757
Blundell, J., Finlayson, G., Axelsen, M., Flint, A., Gibbons, C., Kvist, T., & Hjerpsted, J. B. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12932 · Cited by 693
Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men.
Näslund, E., Barkeling, B., King, N., Gutniak, M., Blundell, J., Holst, J., Rössner, S., & Hellström, P. (1999) · International Journal of Obesity · doi:10.1038/sj.ijo.0800818 · Cited by 468
Fryar, C. D., Carroll, M. D., & Ogden, C. L. (2018) · Cited by 357
GLP-1 and weight loss: unraveling the diverse neural circuitry
Kanoski, S. E., Hayes, M. R., & Skibicka, K. P. (2016) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00520.2015 · Cited by 290
Flagged first, then by citations
2 of the 19 references couldn’t be matched to a known paper.
Research works printed but not linked: 2
- Jain, 2023, Trends shaping the health economy: Value for money, Trilliant Health, 2023, 41
- Tirrell, 2024, At least 25,000 people in the US are starting weight-loss drug Wegovy each week, drugmaker says, CNN Health
Cited by
Sorted by citations
Scragg, J., Koutoukidis, D. A., Dirksen, C., Heitmann, B. L., & Jebb, S. A. (2025) · Med · doi:10.1016/j.medj.2025.100805 · Cited by 16
Fitch, A., Gigliotti, L., & Bays, H. E. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100205 · Cited by 14
Optimizing GLP-1 therapies for obesity and diabetes management
Noronha, J. C., Gaal, L. F. V., Neeland, I. J., Fitch, A., Pfeiffer, A. F. H., Chiavaroli, L., Kendall, C. W. C., & Sievenpiper, J. L. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100222 · Cited by 16
A horizon scan of biological conservation issues for 2026
Sutherland, W. J., Butchart, S. H. M., Clarke, S. J., Doar, N., Doran, H., Douglas, I. C., Field, D. J., Fleishman, E., Gaston, K. J., Herbert‐Read, J. E., et al. (2025) · Trends in Ecology & Evolution · doi:10.1016/j.tree.2025.10.016 · Cited by 8
Johnson, A. J., O’Sullivan, E. N., Valyasevi, P., Metras, B. N., Jang, S., Shields‐Cutler, R. R., Arlinghaus, K. R., Harindhanavudhi, T., & Teigen, L. M. (2026) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2025-0219 · Cited by 10
Metadata
- Authors
- Dilley, A., Adhikari, S., Silwal, P., L. Lusk, J., & McFadden, B. R.
- Corresponding author
- McFadden, Brandon R.
- ORCID
- McFadden, Brandon R.
- Venue
- Food Quality and Preference
- Publisher
- Elsevier BV
- Published
- 2025-08
- Volume
- 129
- Pages
- 105507
- ISSN
- 0950-3293 (ISSN-L)
- OpenAlex
- W4408392848
- Cited by
- 18
- References
- 19
- Citations by year
- 2026: 11 · 2025: 7
- FWCI
- 10.11
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Food Quality and Preference (publishedVersion, cc-by-nc-nd)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Nursing › Nutrition and Dietetics › Nutrition, Health and Food Behavior
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- GLP-1 receptor agonists, dietary intake, food preferences, weight loss, energy intake, processed foods, sugar-sweetened beverages, refined grains, beef consumption, consumer characteristics, dietary behavior change
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
